Medindia

X

EUPROBIO 2008 Presentation to Highlight Latest Immune Research

Monday, October 6, 2008 General News J E 4
Advertisement
BOULDER, Colo., Oct. 6 On Thursday, October 16, 2008 atthe EUPROBIO 2008 Conference, an abstract entitled "Immune regulatorycytokines Del-Immune V(R) induction and its impact on cytotoxicity of naturalkiller cells" will be presented to physicians, researchers and educators.Attendees to the presentation will learn about the latest advancements in thisfield of research. After seeing the study abstract, conference organizers madelast-minute changes to the conference schedule to include a presentation ofthis groundbreaking research.

The abstract is based on a recent study focusing on Del-Immune V(R), a newimmunomodulator containing DNA and peptoglycan fragments of lactobacillusrhamnosus V. The study, which confirms that this formulation enhances immunefunction, was conducted in the Ukraine by several of Europe's foremostresearch scientists.

Among other findings, the study demonstrated that daily administration ofDel-Immune V(R) within 5 days raised a level of circulating interferon up to4.2+/-0.5 log2 u/ml (P <0.05) against 2.0+/-0.3 log2 u/ml of the controls.Interferons are the switches that help cells resist viral infection andprovide the initial, crucial immune response to immune challenges. The resultsof this latest research demonstrate the immune modulator activity ofDel-Immune V(R) and the potential value the dietary supplement may have inclinical situations.

Del-Immune V(R) is a dietary supplement containing a natural culture thatstarts with healthy bacteria originally found in unpasteurized milk. Uniquetechnological processing of the Del-Immune V(R) formulation creates a naturalimmunostimulant. The study described above and other research indicates thatDel-Immune V(R) could be beneficial in assisting the body in its natural roleof protecting the body from germs, viruses and other bodily invaders.

Del-Immune V(R) dietary supplements are produced in the United States.Thousands of people take Del-Immune V(R) on a regular basis and doctors havereported positive results, including an enhanced resistance to cold and fluand a restorative effect on the immune system.

The EUPROBIO 2008 Conference will be held October 15-18, 2008 in Cracow,Poland at Auditorium Maximum.

This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.Contact: Pamela Sichel Pure Research Products, LLC 303-530-7761 http://www.delimmune.com

SOURCE Pure Research Products, LLC
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Dendreon Announces Interim Data From Phase 3 PROVE...
S
deCODE Receives Nasdaq Deficiency Notice Relating ...